Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption. Participants received three infusions of 30 mg kg−1 of each antibody at 0, 3 and 6 weeks. Infusions of the two antibodies were generally well-tolerated. The nine enrolled individuals with antibody-sensitive latent viral reservoirs maintained suppression for between 15 and more than 30 weeks (median of 21 weeks), and none developed viruses that were resistant to both antibodies. We conclude that the combination of the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 can maintain long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs. Combination therapy with the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 maintains long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.

• Publication year

  2018

• Venue

  Nature

• Publication date

  2018-08-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41586-018-0531-2PMID 30258136PMCID 6166473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection

  2018cited by this paper
• Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

  2018cited by this paper
• HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.

  2018cited by this paper
• Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane

  2018cited by this paper
• A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection

  2018cited by this paper
• Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation

  2018cited by this paper
• Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117

  2018cited by this paper
• Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection

  2017cited by this paper
• Early antibody therapy can induce long-lasting immunity to SHIV

  2017cited by this paper
• Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics

  2017cited by this paper
• Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

  2017cited by this paper
• A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

  2017cited by this paper
• Progress toward active or passive HIV-1 vaccination

  2017cited by this paper
• Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA

  2016cited by this paper
• A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

  2016cited by this paper
• Dissecting How CD4 T Cells Are Lost During HIV Infection.

  2016cited by this paper
• Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

  2016cited by this paper
• Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection

  2016cited by this paper
• Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo

  2016cited by this paper
• B-108 Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

  2016cited by this paper
• HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

  2016cited by this paper
• HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

  2016cited by this paper
• Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

  2015cited by this paper
• Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption

  2015cited by this paper
• HIV reservoirs: what, where and how to target them

  2015cited by this paper
• Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

  2015cited by this paper
• HIV-1 integration landscape during latent and active infection.

  2015cited by this paper
• Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

  2015cited by this paper
• The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

  2015cited by this paper
• Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

  2014cited by this paper
• Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

  2014cited by this paper
• Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

  2014cited by this paper
• Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection

  2014cited by this paper
• RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies

  2014cited by this paper
• Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy

  2014cited by this paper
• Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

  2014cited by this paper
• Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

  2014cited by this paper
• Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

  2013cited by this paper
• HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

  2013cited by this paper
• Unravelling the mechanisms of durable control of HIV-1

  2013cited by this paper
• Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

  2013cited by this paper
• HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

  2012cited by this paper
• New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0.

  2010cited by this paper
• A method for identification of HIV gp140 binding memory B cells in human blood.

  2009cited by this paper
• Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing

  2008cited by this paper
• High throughput functional analysis of HIV-1 env genes without cloning.

  2007cited by this paper
• Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection

  2007cited by this paper
• Clustal W and Clustal X version 2.0

  2007cited by this paper
• Medicinal chemistry: Best of both worlds?

  2005cited by this paper
• Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

  1999cited by this paper
• Recombination in HIV-1

  1995cited by this paper

• The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity

  2026cites this paper
• Distinct Antibody Fc-profiles in Lymph During Homeostasis and Chronic HIV Infection.

  2026cites this paper
• Combating Antiviral Drug Resistance: A Multipronged Strategy.

  2026cites this paper
• B Lymphocyte Protein Factories produced by Hematopoietic Stem Cell Gene Editing

  2026cites this paper
• Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies.

  2026cites this paper
• Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study.

  2026cites this paper
• Transcription of HIV-1 is heterogenous among authentic latent CD4+ T cell clones.

  2026cites this paper
• Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.

  2026cites this paper
• HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice.

  2026cites this paper
• Multiple roles of humoral responses in the control of HIV infection.

  2026cites this paper
• Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial.

  2026cites this paper
• Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial

  2026cites this paper
• Q4ddPCR: a flexible, 4-target assay for high-resolution HIV reservoir profiling.

  2026cites this paper
• T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy

  2026cites this paper
• Reduction of the HIV-1 reservoir in T cells from people with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells

  2026cites this paper
• Next-Generation HIV-1 Therapeutics in Co-Endemic Settings.

  2026cites this paper
• Antibodies and T cells join forces for sustained HIV remission

  2025cites this paper
• Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab

  2025cites this paper
• Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir

  2025cites this paper
• SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants

  2025cites this paper
• Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review

  2025cites this paper
• HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies

  2025cites this paper
• Promotion of HIV clearance by sensitization of HIV reservoirs to cell death

  2025cites this paper
• Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children.

  2025cites this paper
• Antibody Polyreactivity: A Challenger of Immune Paradigms

  2025cites this paper
• Current methods for detecting and assessing HIV-1 antibody resistance

  2025cites this paper
• Current treatment of HIV and prospects for cure

  2025cites this paper
• HIV Therapy: The Latest Developments in Antiviral Drugs—A Scoping Review

  2025cites this paper
• HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

  2025cites this paper
• Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation

  2025cites this paper
• Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy

  2025cites this paper
• Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy

  2025cites this paper
• Q4ddPCR (May the Fourth Be Precise): A Flexible, 4-Target Assay for High-Resolution HIV Reservoir Profiling

  2025cites this paper
• Distinct modes of evolution drive HIV escape from two broadly neutralizing antibodies

  2025influential citation
• Passive Immunization in the Prevention and Treatment of Viral Infections

  2025cites this paper
• The Promises and Prospects of Long-acting Therapeutics for Treatment and Prevention of Infectious Diseases

  2025cites this paper
• Future of bNAbs in HIV Treatment

  2025cites this paper
• Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains

  2025cites this paper
• Harnessing mRNA for the expression of monoclonal IgG and IgA in non-human primates

  2025cites this paper
• A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer

  2025cites this paper
• A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning

  2025cites this paper
• Mechanisms of Immune Evasion in HIV-1: The Role of Virus-Host Protein Interactions

  2025cites this paper
• Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data

  2025cites this paper
• A Nonparametric Approach to Practical Identifiability of Nonlinear Mixed Effects Models

  2025cites this paper
• The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure

  2025cites this paper
• The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig

  2025cites this paper
• Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains

  2025cites this paper
• Potent neutralization by antibodies targeting the MPXV A28 protein

  2025cites this paper
• Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives

  2025cites this paper
• Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults.

  2025cites this paper
• VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results

  2025influential citation
• Opportunities and challenges in achieving a functional cure for HIV

  2025cites this paper
• Challenges in the Vaccination of HIV-Infected Individuals

  2025cites this paper
• Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy.

  2025cites this paper
• Gemcitabine combined with baicalein exerts antiviral activity against PEDV by inhibiting the entry and replication phases

  2025cites this paper
• Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the Tatelo Study.

  2025cites this paper
• Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025

  2025cites this paper
• VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials

  2025cites this paper
• Triple rAAV9 Vector Combinations Encoding Broadly Neutralizing Antibodies Effectively Suppress HIV-1 Infection in Humanized Mice

  2025cites this paper
• CD8+ T cell recall cytotoxicity during chronic treated HIV-1 infection is associated with limited reservoir size and activity

  2025cites this paper
• Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial

  2025cites this paper
• CD8+ T cell stemness precedes post-intervention control of HIV viraemia

  2025cites this paper
• Immune-mediated strategies to solving the HIV reservoir problem

  2025cites this paper
• Advances in HIV Treatment: Long-Acting Antiretrovirals and the Path Toward a Cure

  2025cites this paper
• Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope

  2025cites this paper
• Use of broadly neutralizing antibodies in pediatric HIV for treatment and remission

  2025cites this paper
• Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

  2025cites this paper
• Afucosylated broadly neutralising antibodies targeting HIV envelope elicit enhanced NK cell-mediated cytotoxicity against HIV-infected CD4+ T cell and macrophage targets.

  2025cites this paper
• Predicting viral sensitivity to antibodies using genetic sequences and antibody similarities

  2025cites this paper
• Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies

  2025cites this paper
• In vivo evolution of env in SHIV-AD8EO-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig

  2024cites this paper
• Polyfunctionality and breadth of HIV-1 antibodies are associated with delayed disease progression

  2024cites this paper
• Learning patterns of HIV-1 resistance to broadly neutralizing antibodies with reduced subtype bias using multi-task learning

  2024cites this paper
• Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination

  2024cites this paper
• Trade-off between the antiviral and vaccinal effects of antibody therapy in the humoral response to HIV

  2024cites this paper
• Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections

  2024cites this paper
• Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies.

  2024cites this paper
• Post-intervention control in HIV immunotherapy trials

  2024cites this paper
• Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy

  2024cites this paper
• HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

  2024cites this paper
• Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions.

  2024cites this paper
• Parkinson disease therapy: current strategies and future research priorities

  2024cites this paper
• Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV‐1 infected patients in 2020–2023

  2024influential citation
• The impact of analytical treatment interruptions and trial interventions on time to viral re‐suppression in people living with HIV restarting ART in cure‐related clinical studies: a systematic review and meta‐analysis

  2024cites this paper
• HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

  2024cites this paper
• Advanced Therapies for Human Immunodeficiency Virus

  2024cites this paper
• Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing

  2024cites this paper
• Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention

  2024cites this paper
• Impact of antiretroviral therapy during primary HIV infection on T‐cell immunity after treatment interruption

  2024cites this paper
• The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity

  2024cites this paper
• RAIN: a Machine Learning-based identification for HIV-1 bNAbs

  2024cites this paper
• The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity

  2024cites this paper
• RAIN: machine learning-based identification for HIV-1 bNAbs

  2024cites this paper
• Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy

  2024cites this paper
• CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies

  2024cites this paper
• The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

  2024influential citation
• Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention.

  2024cites this paper
• Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS

  2024cites this paper
• Optimising Paediatric HIV Treatment: Recent Developments and Future Directions

  2024cites this paper
• Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection

  2024cites this paper